API | bezlotoxumab

bezlotoxumab (zinplava) Report issue

Biologics mAb Approved ^FDA Fast Track ^FDA Priority Review ^FDA

AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH

Active Ingredient History

NOW

Bezlotoxumab, sold under the brand name Zinplava, is a human monoclonal antibody designed for the prevention of recurrence of Clostridium difficile infections. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules:

bezlotoxumab

mk-6072

gs-cda1

More Chemistry

Pharmacology

Mechanisms of Action:
- Botulinum neurotoxin type A (Clostridium botulinum) ^UniProt
- Toxin B (Peptoclostridium difficile) ^UniProt
Multi-specific: No
Black Box: No
Availability: Prescription Only
Delivery Methods: Missing data
Pro Drug: No

Drug Pricing (per unit)

United States

$2791.2700 - $3819.0500

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

bezlotoxumab | gs-cda1 | mdx-1388 | mk-6072 | zinplava

Organizations (43)

Research & Development (43)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (7)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (7)

Clostridioides difficile (Phase 4)

Clostridium Infections (Phase 4)

Colitis, Ulcerative (Phase 4)

Crohn Disease (Phase 4)

Enterocolitis, Pseudomembranous (Phase 4)

Inflammatory Bowel Diseases (Phase 4)

Sepsis (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 11
# of Trial Organizations: 43

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue